Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve ‘safe’ growth hormone levels. - Lindsay,JR.; McConnell,EM.; Hunter,SJ.; McCance,DR.; Sheridan,B.; Atkinson,AB. (Pituitary, 2004)